Stock SXTP 60 DEGREES PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Market Closed - Nasdaq
Other stock markets
 01:30:00 21/06/2024 am IST 		5-day change 1st Jan Change
0.275 USD +2.80% Intraday chart for 60 Degrees Pharmaceuticals, Inc. -2.41% -73.04%
30/05 60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients CI
20/05 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
AQ
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
AQ
60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients
CI
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
AQ
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
CI
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
AQ
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
AQ
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
AQ
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
CI
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
AQ
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
AQ
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
CI
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
AQ
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
AQ
60 Degrees Pharmaceuticals, Inc. Appoints Kristen Landon as Chief Commercial Officer
CI
60 Degrees Pharmaceuticals Closes $2.4 Million Public Offering
MT
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
PR
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SXTP Stock
  4. News 60 Degrees Pharmaceuticals, Inc.